Advertisement
ALVO vs PAHC
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ALVO is a Hold and PAHC is a StrongBuy.
ALVO's Stochastic Oscillator sits in oversold zone for 8 days
The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.
Technical Analysis (Indicators)
Bullish Trend Analysis
Following a +1.99% 3-day Advance, the price is estimated to grow further. Considering data from situations where ALVO advanced for three days, in 199 of 272 cases, the price rose further within the following month. The odds of a continued upward trend are 73%.
The Aroon Indicator entered an Uptrend today. In 117 of 166 cases where ALVO Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 70%.
Bearish Trend Analysis
The 10-day RSI Indicator for ALVO moved out of overbought territory on September 29, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 26 similar instances where the indicator moved out of overbought territory. In 22 of the 26 cases, the stock moved lower in the following days. This puts the odds of a move lower at 85%.
The Momentum Indicator moved below the 0 level on October 12, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ALVO as a result. In 62 of 99 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 63%.
The Moving Average Convergence Divergence Histogram (MACD) for ALVO turned negative on September 30, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In 36 of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at 78%.
ALVO moved below its 50-day moving average on October 16, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for ALVO crossed bearishly below the 50-day moving average on October 22, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 14 of 15 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ALVO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 79%.
ALVO broke above its upper Bollinger Band on September 18, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 10 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-8.926) is normal, around the industry mean (10.407). P/E Ratio (-7.726) is within average values for comparable stocks, (-6.173). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.152). Dividend Yield (0.000) settles around the average of (0.037) among similar stocks. P/S Ratio (3.071) is also within normal values, averaging (178.797).
The Tickeron Price Growth Rating for this company is 40 (best 1 - 100 worst), indicating steady price growth. ALVO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ALVO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock worse than average.
Momentum Indicator for PAHC turns positive, indicating new upward trend
PAHC saw its Momentum Indicator move above the 0 level on September 29, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 85 similar instances where the indicator turned positive. In 65 of the 85 cases, the stock moved higher in the following days. The odds of a move higher are at 76%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for PAHC just turned positive on October 01, 2026. Looking at past instances where PAHC's MACD turned positive, the stock continued to rise in 34 of 45 cases over the following month. The odds of a continued upward trend are 76%.
PAHC moved above its 50-day moving average on September 30, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for PAHC crossed bullishly above the 50-day moving average on October 07, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 10 of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 67%.
Following a +2.60% 3-day Advance, the price is estimated to grow further. Considering data from situations where PAHC advanced for three days, in 214 of 285 cases, the price rose further within the following month. The odds of a continued upward trend are 75%.
The Aroon Indicator entered an Uptrend today. In 171 of 247 cases where PAHC Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 69%.
Bearish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PAHC declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 74%.
PAHC broke above its upper Bollinger Band on October 02, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is 34 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 47 (best 1 - 100 worst), indicating steady price growth. PAHC’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 51 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.193) is normal, around the industry mean (10.407). P/E Ratio (16.183) is within average values for comparable stocks, (-6.173). Projected Growth (PEG Ratio) (0.350) is also within normal values, averaging (2.152). Dividend Yield (0.012) settles around the average of (0.037) among similar stocks. P/S Ratio (0.953) is also within normal values, averaging (178.797).
The Tickeron Profit vs. Risk Rating rating for this company is 60 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock slightly better than average.
The Tickeron PE Growth Rating for this company is 90 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
ALVO | PAHC | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 75 | 40 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 10 Undervalued | 51 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | 60 | |
SMR RATING 1..100 | 100 | 34 | |
PRICE GROWTH RATING 1..100 | 40 | 47 | |
P/E GROWTH RATING 1..100 | 97 | 90 | |
SEASONALITY SCORE 1..100 | 75 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
ALVO's Valuation (10) in the null industry is somewhat better than the same rating for PAHC (51) in the Pharmaceuticals Major industry. This means that ALVO’s stock grew somewhat faster than PAHC’s over the last 12 months.
PAHC's Profit vs Risk Rating (60) in the Pharmaceuticals Major industry is somewhat better than the same rating for ALVO (100) in the null industry. This means that PAHC’s stock grew somewhat faster than ALVO’s over the last 12 months.
PAHC's SMR Rating (34) in the Pharmaceuticals Major industry is significantly better than the same rating for ALVO (100) in the null industry. This means that PAHC’s stock grew significantly faster than ALVO’s over the last 12 months.
ALVO's Price Growth Rating (40) in the null industry is in the same range as PAHC (47) in the Pharmaceuticals Major industry. This means that ALVO’s stock grew similarly to PAHC’s over the last 12 months.
PAHC's P/E Growth Rating (90) in the Pharmaceuticals Major industry is in the same range as ALVO (97) in the null industry. This means that PAHC’s stock grew similarly to ALVO’s over the last 12 months.
| ALVO | PAHC | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 85% | N/A |
| Stochastic ODDS (%) | 1 day ago 73% | 1 day ago 73% |
| Momentum ODDS (%) | 1 day ago 63% | 1 day ago 76% |
| MACD ODDS (%) | 1 day ago 78% | 1 day ago 76% |
| TrendWeek ODDS (%) | 1 day ago 75% | 1 day ago 71% |
| TrendMonth ODDS (%) | 1 day ago 78% | 1 day ago 75% |
| Advances ODDS (%) | 2 days ago 73% | 1 day ago 75% |
| Declines ODDS (%) | 9 days ago 79% | 10 days ago 74% |
| BollingerBands ODDS (%) | 3 days ago 68% | 1 day ago 68% |
| Aroon ODDS (%) | 1 day ago 70% | 1 day ago 69% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ALVO’s FA Score shows that 1 FA rating(s) are green while PAHC’s FA Score has 0 green FA rating(s).
- ALVO’s FA Score: 1 green, 4 red.
- PAHC’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ALVO’s TA Score shows that 4 TA indicator(s) are bullish while PAHC’s TA Score has 5 bullish TA indicator(s).
- ALVO’s TA Score: 4 bullish, 6 bearish.
- PAHC’s TA Score: 5 bullish, 4 bearish.
Price Growth
ALVO (@Pharmaceuticals: Generic) experienced а -9.79% price change this week, while PAHC (@Pharmaceuticals: Generic) price change was +3.48% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was -3.00%. For the same industry, the average monthly price growth was -9.86%, and the average quarterly price growth was +9.31%.
Reported Earning Dates
ALVO is expected to report earnings on Nov 11, 2026.
PAHC is expected to report earnings on Nov 04, 2026.
Industries' Descriptions
@Pharmaceuticals: Generic (-3.00% weekly)A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.
Advertisement
ALVO and
Correlation & Price change
A.I.dvisor tells us that ALVO and CRON have been poorly correlated (+24% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that ALVO and CRON's prices will move in lockstep.
| Ticker / NAME | Correlation To ALVO | 1D Price Change % | ||
|---|---|---|---|---|
| ALVO | 100% | -6.63% | ||
| CRON - ALVO | 24% Poorly correlated | +1.62% | ||
| EBS - ALVO | 23% Poorly correlated | +0.48% | ||
| PAHC - ALVO | 22% Poorly correlated | +1.43% | ||
| ACB - ALVO | 22% Poorly correlated | +0.25% | ||
| LFCR - ALVO | 21% Poorly correlated | N/A | ||
More | ||||
PAHC and
Correlation & Price change
A.I.dvisor indicates that over the last year, PAHC has been loosely correlated with ZTS. These tickers have moved in lockstep 61% of the time. This A.I.-generated data suggests there is some statistical probability that if PAHC jumps, then ZTS could also see price increases.
| Ticker / NAME | Correlation To PAHC | 1D Price Change % | ||
|---|---|---|---|---|
| PAHC | 100% | +1.43% | ||
| ZTS - PAHC | 61% Loosely correlated | +2.99% | ||
| ELAN - PAHC | 47% Loosely correlated | +0.62% | ||
| VTRS - PAHC | 29% Poorly correlated | +0.16% | ||
| LFCR - PAHC | 27% Poorly correlated | N/A | ||
| AKBA - PAHC | 26% Poorly correlated | -3.95% | ||
More | ||||